文献速递消化系统肿瘤

白蛋白紫杉醇联合吉西他滨加或不加卡培他滨和顺铂治疗局部晚期或交界可切除胰腺癌的随机II期试验

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
PubMed 文献 · Eur J Cancer · 2018-08-24

这项随机II期试验评估在AG方案基础上联合顺铂和卡培他滨(PAXG方案)治疗局部晚期或交界可切除PDAC的可行性和活性,主要终点为肿瘤切除率。54例患者随机分入PAXG组(26例)或AG组(28例),切除率分别为31%和32%,1年PFS分别为58%和39%,18个月OS分别为69%和54%。结论认为PAXG方案可行且疾病控制结果有前景,值得进一步III期研究。

要点

  • PAXG组和AG组的切除率分别为31%和32%。
  • PAXG组1年PFS为58%,AG组为39%;PAXG组18个月OS为69%,AG组为54%。
  • 在AG基础上联合顺铂和卡培他滨可行,且未对耐受性造成不利影响。

核心结论

  • 在AG方案基础上联合顺铂和卡培他滨(PAXG)治疗局部晚期或交界可切除PDAC可行,疾病控制结果有前景,且未对耐受性造成不利影响。
  • 该方案值得进一步开展III期研究。

研究设计与样本

  • 随机II期试验,纳入54例年龄18至75岁、病理诊断为局部晚期或交界可切除PDAC的初治患者。
  • 患者随机分入PAXG组(arm A,N=26)或AG组(arm B,N=28)。
  • 主要终点为肿瘤切除率,若至少完成4例切除则视为治疗有活性;次要终点包括PFS、OS、RECIST缓解率、Hartman病理缓解、CA19.9缓解率和毒性。

主要发现

  • PAXG组8例(31%)和AG组9例(32%)接受了切除。
  • 1年PFS在PAXG组为58%,在AG组为39%。
  • 18个月OS在PAXG组为69%,在AG组为54%。

关键数值与推荐

  • 主要终点肿瘤切除率:PAXG组31%(8/26),AG组32%(9/28)。
  • 1年PFS:PAXG组58%,AG组39%;18个月OS:PAXG组69%,AG组54%。
  • 若至少完成4例切除,则治疗被认为有活性。

临床怎么用

  • 对于局部晚期或交界可切除PDAC,可考虑在AG方案基础上联合顺铂和卡培他滨(PAXG),该方案可行且耐受性未受不利影响。
  • 该方案目前仍属研究性,需进一步III期研究验证后再用于常规临床决策。

局限性

  • 为II期随机试验,样本量有限(共54例),结果需III期研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current trial assessed whether the addition of cisplatin and capecitabine to the nab-paclitaxel-gemcitabine backbone is feasible and active against borderline and locally advanced pancreatic adenocarcinoma (PDAC). METHOD: Fifty-four chemo-naive patients, aged between 18 and 75 years, with a pathological diagnosis of locally advanced or borderline resectable PDAC were randomised to receive either nab-paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26) or nab-paclitaxel followed by gemcitabine (AG; arm B; N = 28). The primary end-point was the tumour resection rate. If at least four such resections were performed, the treatment was considered as active. The secondary end-points were progression-free survival (PFS), overall survival (OS), Response Evaluation Criteria in Solid Tumours response rate, Hartman's pathologic response, carbohydrate antigen 19.9 response rate and toxicity. RESULTS: Eight patients (31%) in the PAXG arm and nine (32%) in the AG arm underwent resection. PFS at 1-year was 58% in arm A and 39% in arm B. OS at 18-month was 69% in arm A and 54% in arm B. CONCLUSIONS: In this phase II study, the addition of cisplatin and capecitabine to the AG backbone was feasible and yielded promising results in terms of disease control without detrimental impact on tolerability. The approach warrants further investigation in a phase III study. TRIAL REGISTRATION: NCT01730222.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018. PMID: 30149366. doi:10.1016/j.ejca.2018.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。